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Abstract
Background: Cytomegalovirus (CMV) is the most common opportunistic infection following lung transplantation.
CMV replication in the lung allograft is described as accelerating the development of bronchiolitis obliterans
syndrome (BOS). Finding a strategy to prevent CMV infection is an important issue.
Methods: We performed a retrospective, single-centre study of 114 lung transplant recipients (LTRs) who
underwent lung transplantation from January 2001 to December 2006. In a smaller cohort of 88 CMV
seropositive (R+) LTRs, three months of valganciclovir prophylaxis (2004-2006) was compared to three months
of oral ganciclovir (2001-2003) with respect to the incidence of CMV infection/disease, the severity of CMV
disease, acute rejection, BOS-free 4 year survival and 4 year survival. In the whole group of 114 LTRs the impact
of CMV infection on long-term survival (BOS free 4 year survival and 6 year survival) was assessed.
Results: For the cohort of 88 CMV seropositive LTRs, the incidence of CMV infection/disease at one year was
lower in the valganciclovir group compared to the ganciclovir group (24% vs. 54%, p = 0.003). There was a
tendency towards reduced CMV disease, from 33% to 20% and a significant lower incidence of asymptomatic
CMV infection (22% vs. 4%, p = 0.005). A lower incidence of acute rejection was observed in the valganciclovir
group. However, there was no significant difference between the two groups in BOS free 4 year survival and
4 year survival.
For the entire group of 114 LTRs, BOS-free 4 year survival for recipients with CMV disease was (32%, p = 0.005)
and among those with asymptomatic CMV infection (36%, p = 0.061) as compared with patients without CMV
infection (69%). Six year survival was lower among patients with CMV disease, (64%, p = 0.042) and asymptomatic CMV
infection (55%, p = 0.018) than patients without CMV infection (84%).
Conclusions: A lower incidence of CMV infection/disease and acute rejections was observed with valganciclovir
(3 months) when compared to oral ganciclovir (3 months). The long-term impact of CMV infection/disease was
significant for BOS-free survival and survival.
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Background
Cytomegalovirus (CMV) is the most clinically significant
opportunistic infection that can occur following lung
transplantation (LTx). The reported incidence of CMV
infection/disease ranges from 38% to 75% in lung transplant
recipients (LTRs) in the absence of any prophylaxis [1]. In
addition, CMV infections can have indirect effects; such as
allograft rejection, diminished graft and patient survival as
well as a predisposition for opportunistic infections
and malignancies [2,3]. Finding strategies to prevent
CMV infection/disease is a major challenge following
lung transplantation. In a previous study of 187 LTRs
we reported that oral ganciclovir (GCV) prophylaxis
for 3 months delayed the onset and reduced the severity
of CMV disease when compared to intravenous (IV)
ganciclovir for 4 weeks [4]. Today, IV GCV followed by
VGCV or VGCV alone are the most common prophylaxis
strategies [5]. However, there is no consensus on the
optimal duration of prophylaxis for LTRs. Valganciclovir is
a prodrug of ganciclovir with greater bioavailability
(60%) than oral GCV (6%) and oral GCV 1000 mg t.i.d.is
equivalent to VGCV 450 mg daily [6].
The main cause of long-term morbidity and mortality
in LTRs is bronchiolitis obliterans syndrome (BOS)
that is present in 49% of recipients 5 years after lung
transplantation and at 10 years the rate reaches 75% [7].
BOS is a chronic allograft dysfunction/chronic rejection
that is defined as a progressive airflow obstruction not
explained by acute rejection, infection or other confounding
complication [8]. CMV replication in lung allograft is
described as accelerating the development of BOS [9-13].
The aims of this study were to compare 3 months of
CMV prophylaxis using oral ganciclovir with 3 months
of valganciclovir with respect to incidence and severity
of CMV disease and to study the impact of CMV infec-
tion/disease on long-term outcomes/survival.
Methods
Patient population and study design
Medical records on patients transplanted between January
2001 and December 2006 were reviewed. During the study
period 128 lung transplantations were performed. Of these,
117 transplantations in 114 patients were selected for
inclusion. Six patients who died within 30 days of
transplantation and five re-transplantations were excluded.
CMV infection, acute cellular rejection (AR) and BOS related
to the initial lung transplantation were evaluated. Clinical
episodes of CMV infection and AR at 12 months were eval-
uated. BOS development was followed annually. Follow-up
on all patients was complete on January 20, 2011.
The primary goal of the study was to compare
3 months of prophylaxis with VGCV to GCV in both the
short and long term. To exclude the influence of CMV
serostatus, only the 88 patients with R + were included in
this first cohort. All patients received VGCV or GCV;
which was the standard care for CMV prophylaxis to R + .
A secondary goal was to assess the impact of CMV
infection/disease (regardless of prophylaxis) on the devel-
opment of BOS and survival. In this part of the study,
both R + and R- patients were included to get a larger
group (i.e. the second cohort).
This research was approved by the local Ethical Committee
at Gothenburg University Hospital, Gothenburg, Sweden
and it follows the applicable standards set by the Declaration
of Helsinki; reference number Ö 393-01.
Data collection
To identify CMV episodes; clinical parameters such as
fever, cough, dyspnoea, hypoxemia and other clinical
signs or symptoms mentioned in a clinical record were
recorded as well as results from transbronchial biopsy
(TBB) and bronchoalveolar lavage (BAL) to detect CMV
infection, (ie.histopathology with CMV inclusion bodies and
IHC analyses with monoclonal antibodies against CMV).
Analyses of CMV replication by PCR were registered if it
was performed, (i.e.in our study quantitative analysis of
CMV DNA in serum). Results from TBB were collected to
exclude or verify acute rejections.
Data from regular appointments was also collected to
detect CMV infection (for details see the section on
postoperative follow-up). Spirometry with FEV1, to annu-
ally evaluate BOS development.
Immunosuppression
Induction therapy used antithymocyte globulin (ATG)
with an initial dose of 2.0 mg × 1 followed by 1.5 mg ×
1. The doses were based on daily CD3-positive T lympho-
cyte cell counts and were given until the concentration of
cyclosporine was 350 ng/ml, (in most cases 2-4 doses of
ATG). Together with ATG, 500 mg of methylprednisolone
was given twice the day of transplantation; following
surgery 125 mg of methylprednisolone was administered
every 8 hours for a total of 3 doses.
All patients received triple immunosuppressive therapy
that used cyclosporine (CsA), mycophenolate mofetil
(MMF) and prednisone. The dose of CsA was monitored so
as to give an initial trough level of 350 ng/ml (0-3 months).
This level was tapered to 300 ng/ml (3-6 months) and lastly
tapered to 200-150 ng/ml at 6 months. MMF was given in
the dose of 1.5 g × 2/day which was then reduced down to
1 g × 2/day after 3 months. Oral prednisone was initially
given at the rate of 0.3 mg/kg/day (0-3 months). It was then
tapered to 0.2 mg/kg/day (3-6 months) and finally tapered
to 0.1 mg/kg/day at 6 months. If MMF was not tolerated
it was switched to azathioprine (Aza) at the rate of
2 mg/kg/day. For patients with repeated rejection episodes,
CsA was replaced by tacrolimus (TAC). The dose of
TAC was monitored to maintain an initial trough level
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of 25-15 ng/ml (0-3 months). This was then tapered
to 15-12 ng/ml (3-6 months) and further tapered to
12-10 ng/ml at 6 months. No or minimal changes were
made in the immunosuppressive regimes during 2001-2003
when oral GCV was used as prophylaxis and from 2004 to
2006 when VGCV was used as prophylaxis.
CMV prophylaxis
All R + patients were given oral GCV 1000 mg three times
a day for 3 months. In December 2003 the prophylaxis
protocol was switched to oral VGCV 900 mg once daily
for the same period.
All D+/R- patients were given oral GCV 1000 mg three
times a day for three months together with CMVIG
(Megalotect®) 50 E/kg/day on days 0, 7, 14, 35, 56 and 77
after transplantation. In December 2003 the prophylaxis
was switched to oral VGCV 900 mg once daily for
6 months; plus 6 doses of CMVIG over the same time
frame as described in the last sentence.
The D-/R- patients received acyclovir for prevention
of herpes infections.
IV GCV (except to R-) was used if a patient was not
able to take oral medication. Doses of all drugs were
adjusted for renal function.
CMV treatment
The treatment for CMV disease and asymptomatic
CMV infection verified by a lung biopsy was IV GCV
5 mg/kg twice daily for 10 to 21 days (sometimes longer).
Patients with hypoxia also received polyclonal immuno-
globulin (Gammagard®) at a dose of 0.5 g/kg every other
day until improvement (maximum 5 doses). Patients who
did not respond to GCV or who had severe bone marrow
suppression were treated with foscarnet. A control biopsy
was performed 4 weeks after the start of treatment. If
needed, at least 2 more weeks of IV GCV 5 mg/kg twice
daily was added. If CMV pneumonitis was not diagnosed,
no further prophylaxis was given.
Postoperative follow-up and monitoring
Regular appointments at the transplant unit, with clinical,
radiological and pulmonary function evaluation and surveil-
lance bronchoscopy using TBB/BAL were scheduled ½, 1,
2, 3, 4½, 6, 9, 12, 18 and 24 months after transplantation
and then annually.
Pulmonary function tests consisted of spirometry
(forced vital capacity - FVC), forced expiratory volume in
1 second (FEV1), measurements of lung volume (total lung
capacity - TLC), functional residual capacity (FRC), residual
volume (RV), carbon monoxide - CO uptake (i.e. transfer
factor/diffusing capacity) and the single breath N2 test.
TBB and BAL were also used if infection or rejection was
suspected.TBB and BAL were repeated 4 weeks after
episodes of acute rejection.
TBB samples were used for histopathologic examination
including evaluation of acute or chronic rejection, the
opportunistic fungus Pneumocystis jiroveci and CMV
infection. Evaluation of CMV infection was performed
using immunohistochemistry (IHC) with monoclonal
antibodies against CMV.
BAL samples were cultured for fungi and bacteria,
including Legionella and mycobacteria,
BAL samples were examined microscopically for CMV
inclusion bodies, Pneumocystis jiroveci, other fungi and
mycobacteria, throughout the study period.
From 2001 to 2006 all follow-ups were carried out
using the same protocol.
Definitions
Asymptomatic CMV infection
Detection of viral inclusion bodies (‘owl’s eye’) or a positive
immunohistochemistry (IHC) in TBB and/or BAL together
with parenchymal diffuse or perivascular inflammation
or CMV DNA detected in serum, but with no clinical
symptoms.
Mild CMV pneumonitis
In addition to CMV infection, at least 1 of the following
signs and/or symptoms: subfebrility (≥ 37.5–37.9°C) ≥ 1 day,
dyspnoea, cough or decreased FEV1 and/or decreased
CO diffusion.
Moderate CMV pneumonitis
In addition to CMV infection, at least 2 of the following
signs and/or symptoms: fever ≥ 38°C for ≥ 1 day, dyspnoea,
cough or decreased FEV1 and/or decreased CO diffusion
or white blood cell count (WBC) < 4 × 109/l or platelet
count < 100 × 109/l.
Severe CMV pneumonitis
In addition to CMV infection, treatment with continuous
positive airway pressure (CPAP) or ventilator was required,
or had CMV-related mortality.
Prolonged CMV pneumonitis
CMV was found in TBB and/or BAL after 4 weeks
or more.
Gastrointestinal CMV disease
Clinical symptoms such as nausea, vomiting, epigastric
pain, diarrhoea, abdominal cramps, together with an endo-
scopically proven ulcer having microscopic mucosal lesions.
If CMV is detected by a positive IHC of the biopsy, we
define it as a ‘proven’ gastrointestinal CMV disease. If CMV
DNA only was found in serum or the biopsy we call it
‘probable’ gastro-intestinal CMV disease. If a patient had
severe symptoms from the gastrointestinal tract and pos
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CMV DNA in serum, but no endoscopy was performed, we
call it ‘possible’ gastrointestinal CMV disease.
CMV syndrome
Fever, leucopenia or thrombocytopenia together with CMV
DNA in serum and no other cause of symptoms/signs
identified.
TBB was routinely evaluated morphologically together
with immunohistochemistry (IHC) using monoclonal
antibodies to identify early and late CMV antigens
(Avidin-Biotin Complex Method for IHC Detection).
The same IHC has been used during the study period.
CMV DNA in serum was analyzed by quantitative
real-time PCR.
These definitions are based on a modified version
from a publication by Ljungman et al [14]. The following
definitions; the severity of CMV pneumonitis, prolonged
CMV pneumonitis and possible gastrointestinal CMV
disease are not generally accepted. The authors have found
the definitions useful when it’s necessary to describe the
symptoms more clearly.
Bronchiolitis obliterans syndrome (BOS) is defined as a
baseline of forced expiratory volume in 1 second (FEV1)
calculated as a mean of the two best measurements
obtained at the 2, 3, 4.5, 6 and 9 month follow-up
appointments at the transplant unit following transplant-
ation. This baseline value is used for comparison with
FEV1 values measured later and to calculate a patient’s
BOS grade. BOS grade 1 has an FEV1 of 65-80%, BOS
grade 2 has an FEV1 of 50%-65% and BOS grade 3 and
FEV1 less than 50% of the baseline value.
Obliterative bronchiolitis (OB) is the histological correlate
of chronic allograft rejection; a peribronchiolar infiltration of
lymphocytes, leading to fibrous scaring in the bronchioles.
Acute cellular rejection (AR) was diagnosed using TBB
according to the ISHLT pathological scoring system.
(A1 =minimal AR, A2 =mild AR, A3 =moderate AR,
A4 = severe AR).
Cumulative acute rejection score (CAR score) was
defined as the cumulative grading of AR ≥ 1 (e.g. A1 +A1 +
A2 =CAR score of 4) [15].
CAR score /TBB are defined as an individual’s CAR
score divided by their measurable TBB [11].
Statistical analyses
Descriptive statistics were calculated for continuous variables,
frequencies and proportions for categorical variables. The
Chi-square test was used to compare proportions and
occurrences between the groups. When the median was
assessed, the statistical comparisons used the Mann-
Whitney test. Confidence intervals were calculated using
a normality approximation algorithm. The survival ana-
lysis in Figures 1 and 2 used the Kaplan–Meier procedure.
Comparisons of survival distributions between different
categories were made using the log rank test. For the data
used in Figure 1, patients without BOS information were
excluded; except for those who died within one year of
transplantation. Statistical significance was set at the 5%
level i.e. p-value <0.05. Data was analyzed using SPSS
version 20.
Results
The demographics for the 114 LTRs are presented in
Table 1. There were 72 woman (63%). The mean age of
all members of the group was 49 years. The most frequent
pre transplant diagnoses were chronic obstructive pulmon-
ary disease (COPD) of 38%, idiopathic pulmonary fibrosis
(IPF) of 20% and alpha-1 antitrypsin deficiency with
emphysema (A1AT) of 18%. Single lung transplantation
was performed with 70% of the recipients.
Oral GCV versus VGCV for 3 months in 88 R + recipients
The demographics for the 88 LTRs are presented in
Table 2. The demographics were equal concerning age and
diagnosis; single lung transplantation was slightly more
common in the GCV group (78% vs. 71%).
Follow up for CMV infection was 12 months. The
incidence of CMV infection/disease was lower in the
VGCV prophylaxis group than in the GCV group
(24% vs. 54%, p = 0.003). There was also a trend towards
lower incidence of CMV disease in the VGCV group
(20% vs. 33%, p = 0.17), see Table 3.
Figure 1 BOS-free survival in 107 lung transplant recipients
related to CMV disease. No CMV infection (n = 65), Asymptomatic
CMV infection (n = 11), CMV disease (n = 31). BOS-free 4 year survival
for patients with CMV disease was 32%, (p = 0.005), for asymptomatic
CMV infection 36%, (p = 0.061) as compared with patients without
CMV infection (69%).
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In our study, 6% (5/88) had CMV infection diagnosed
by CMV-DNA in serum. In the GCV group 2 patients
were diagnosed with CMV DNA in serum (one with
CMV syndrome and the other with possible gastrointes-
tinal CMV disease). In the VGCV group three patients
were diagnosed with CMV DNA in serum (one with an
asymptomatic CMV infection and two with CMV
syndrome).
From the medical records reviewed we found that 4
individuals in the R + cohort were diagnosed by a phys-
ician as having gastrointestinal CMV disease. Three
had severe upper gastrointestinal tract symptoms and
pos CMV DNA in serum; the fourth had lower
gastrointestinal tract symptoms plus verified CMV
pneumonitis.
With three exceptions, the onset of CMV infection
in the VGCV group was between 147 and 201 days
post-transplantation. Two of the three had no or
inadequate CMV prophylaxis owing to renal failure
(onset of CMV infection was for these two 23 and
32 days post-transplantation) and for the patient with a
probable GCV resistant, the onset of CMV infection
was at 62 days. Data for the length of CMV prophy-
laxis was missing for 2 of the persons in the GCV
group and for 3 from the VGCV group; the remainder
received prophylaxis for a median of 89 (GCV) or 90
(VGCV) days.
Acute rejections (AR) were studied for 12 months. AR
was less frequent in the VGCV group during the entire first
year, se Table 4. The CAR score divided by the number of
evaluable TBBs and one or two treatable acute rejections
(i.e. AR grade ≥ 2) were decreased in the VGCV group.
BOS-free survival and survival in R+
BOS-free 4 year survival in R + (both the GCV and
VGCV groups) was 30% for patients with CMV disease
and 67% for those without CMV infection (p = 0.018).
There was no significant difference in long-term outcome
(i.e. 4 year survival and BOS-free 4 year survival) between
the GCV and VGCV prophylaxis groups.
BOS and OB in R+
In the GCV group 32% (12/37) were diagnosed with
BOS (measured with FEV1) or OB (diagnosed by biopsy).
Six of these patients died and one was re-transplanted
owing to BOS.
Figure 2 Survival in 114 lung transplant recipients related to
CMV disease. No CMV infection (n = 70), Asymptomatic CMV infection
(n = 11), CMV disease (n = 33). Six year survival was lower among
patients with CMV disease, (64%, p = 0.042) and asymptomatic CMV
infection (55%, p = 0.018) than patients without CMV infection (84%).
Table 1 Demographics for the 114 lung transplant
recipients in the study
Characteristics N = 114
LTx, years 2001-2006
Recipient Age years, mean (range) 49 (10-68)
Female (%) 63
Donor Age years, mean (range) 42 (5-70)
Female (%) 55
CMV serostatus, n (%) D+/R+: 66 (58)
D-/R+: 22 (19)
D+/R-: 17 (15)
D-/R -: 9 (8)
Tx type n (%)
-Single 80 (70)
-Double 31 (27)











R = recipient, D = donor, COPD = chronic obstructive pulmonary disease,
CF = Cystic fibrosis, A1AT = alpha-1 antitrypsin deficiency with emphysema,
IPF = idiopathic pulmonary fibrosis, PAH = pulmonary arterial hypertension,
PH = pulmonary hypertension, GVHD = graft-versus-host disease.
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In the VGCV group 24% (12/51) were diagnosed
with BOS/OB. Two of these patients died and 2 were
re-transplanted owing to BOS.
Mortality in R+
In the GCV group, a total of 27% (10/37) died within
4 years. Six of these individuals died of BOS. Two died
of malignancies, one of infection (not CMV infection)
and one of lung bleeding.
In the VGCV group 20%, (10/51) of the patients died
within 4 years. Two died of BOS, two of malignancies
and six patients died of infections. (One of them died
owing to CMV disease).
Episodes of CMV infection or disease during the first
12 months in 114 lung transplants recipient (R + and R-)
Demographics are shown in Table 1. Follow-up for CMV
infection was 12 months.
The impact of CMV serostatus was essential for onset of
CMV infection. The incidence of CMV infection/disease
was for D+/R- 65%, for D+/R + 39% for D-/R + 27% and
for D-/R- 11% (p = 0.03).
CMV disease was found in 29% (33/114) of the study par-
ticipants. Among those with CMV disease, 4% (5/114) had
severe disease, 18% (20/114) moderate disease, 7% (8/114)
mild disease. Asymptomatic CMV infection was found in
10% (11/114) and no CMV infection was found in
61% (70/114) of the study group. In this cohort only
5% (6/114) were diagnosed with CMV DNA in serum.
Gastrointestinal (GI) CMV disease was seen in 8%
(9/114) of the study group. Four patients from the
high risk group (D+/R-) had proven GI CMV disease.
One individual from the low risk group (D-/R-) suffered
from a primary infection and had a proven GI CMV
disease (as well as CMV pneumonitis). Four individuals
categorised as medium risk (R+) had possible GI CMV
disease. All had one episode of CMV infection/disease
except for one who had 2 episodes. Prolonged CMV
episodes were found in 9% (10/114) of the entire study
group. In the high-risk group 35% (6/17) had a prolonged
CMV episode.
Long-term follow up in 114 lung transplant recipients
(R + and R-) according to the development of CMV infection
BOS-free survival in the total group (R + and R-)
BOS-free 4 year survival (i.e. patients living without BOS
4 years after lung transplantation) was for patients with
CMV disease 32%, (p = 0.005), for asymptomatic CMV
infection 36%, (p = 0.061) as compared with patients
without CMV infection, 69%, see Figure 1. BOS data was
available for 107 of the 114 patients. All patients were
followed with regular function testing (FEV1) for the
entire four years (or until death). BOS-free survival was
on the average 2.9 (95% CI; 2.6-3.2) years for the total
group. Patients without CMV infection were free from
BOS for 8.4 months longer than those with a CMV
disease/infection. Patients with D+/R- had the shortest
time until the detectable onset of BOS.
Survival in the total group (R + and R-)
Six year survival was lower among patients with CMV
disease, (64%, p = 0.042) and asymptomatic CMV infection
(55%, p = 0.018) as compared with patients without CMV
infection (84%). Six year survival for the entire group
of 114 patients was 75% see Figure 2. No patients were
lost to follow-up tracking. Four of the 11 patients with
asymptomatic CMV infection died early - 2 of malignancy,
2 of infection (not CMV infection). The deaths of 4
out of 11 may at least partially explain the apparently
poor responses among the study participants with
asymptomatic CMV infection.






(n = 37) (n = 51)
LTx, years 2001-2003 2004-2006
Recipient age years, mean (range) 49 (15-64) 52 (13-67)
Female (%) 68 63
Donor age years, mean (range) 40 (11-61) 42 (5-70)
Female (%) 51 57















-Pulmonary embolism 0 4
None of the differences were statistically significant.
COPD = chronic obstructive pulmonary disease, CF = Cystic fibrosis,
A1AT = alpha-1antitrypsin deficiency with emphysema, IPF = idiopathic
pulmonary fibrosis, PAH = pulmonary arterial hypertension,
GVHD = graft-versus-host disease.
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GCV resistant CMV
Two patients were treated with foscarnet. One had a proven
GCV resistance (mutation in the CMV UL 97 gene). The
other had a rapid response after being switched from
ganciclovir to foscarnet but no resistance test was
performed. CMV serostatus for these two were D+/R- and
D+/R + .
Discussion
Oral prophylaxis with VGCV seemed to be more effective
than GCV among the LTRs studied. A lower incidence of
CMV infection/disease at one year was observed, 24%
versus 54% (p < 0.003), mainly due to a reduction of
asymptomatic CMV infection from 22% to 4%. Montforte
et al performed a similar study comparing 120 days of
VGCV to GCV prophylaxis in LTRs and they found a
lower rate of CMV disease in the VGCV group, 16 versus
8%, but the difference did not reach statistical significance
[16]. There was no difference in the rate of asymptomatic
CMV infection. In their study regular monitoring by shell
vial or CMV antigenemia assay was performed while in
our study we monitored frequently with surveillance
TBBs including IHC diagnosis. Only a few patients
were diagnosed with CMV infection/disease solely on
the basis of positive CMV DNA in serum. Monitoring
of blood, today mostly done by molecular assays,
might lead to earlier detection of asymptomatic CMV
infection which enables treatment and prevention of
CMV disease. Our extensive use of surveillance TBBs
could also be a contributing factor to our higher rate
of tissue-invasive CMV disease.
There was no difference between GCV and VGCV treat-
ment regarding the time for onset of CMV infection/disease
or the number of prolonged CMV episodes. The rate of
gastrointestinal disease, 4-5%, was also similar in the groups.
Gastrointestinal CMV may be underreported in our
study since patients with verified CMV pneumonitis
treated with IV GCV who at the same time had gastro-
intestinal symptoms were not regularly undergoing an
endoscopy.
Our centre uses ATG as induction therapy, which is
supposed to give a higher rate of CMV disease. However,
the monitoring with CD3-positive T-cells has made it
possible to reduce ATG by 50% as compared to our previ-
ous fixed dose of ATG, why it now should only have
limited effect on the rate of CMV disease. We found
that CMV disease was still 20% at 1 year with VGCV
prophylaxis for 3 months. It may be possible to further
reduce this rate with a longer prophylaxis and frequent
monitoring with quantitative CMV PCR after cessation
of VGCV prophylaxis. CMV prophylaxis after lung trans-
plantation varies widely between centres; most follow a
regimen that has 3-6 months of prophylaxis with IV GCV
or VGCV with or without CMVIG [5]. Recent studies
recommend extending prophylaxis for LTRs [17-22].
Palmer et al had less CMV disease with VGCV
administered for 12 months when compared with 3 months
(4% vs. 32%, p < 0.001) [21].
Table 3 Episodes of CMV infection or disease during the first 12 months in 88 CMV- seropositive (R+) lung
transplant recipients
CMV infection or disease Oral ganciclovir 3 months Valganciclovir 3 months p-value
(n %) n = 37 n = 51
LTx, years 2001-2003 2004-2006
No CMV, n (%) 17 (46) 39 (76)
CMV infection/disease, n (%) 20 (54) 12 (24) 0.003
CMV disease -Total n (%) 12 (33) 10 (20) 0.170
-Severe 0 2 (4)
0.262-Moderate 8 (22) 5 (10)
-Mild 4 (11) 3 (6)
Asymptomatic CMV inf., n (%) 8 (22) 2 (4) 0.005
Prolonged CMV episode, n (%) 1 (3) 2 (4) 0.756
Gastrointestinal CMV inf., n (%) 2 (5) 2 (4) 0.741
Ganciclovir resistance, n (%) 0 1 (2) 0.392
Onset of CMV inf/disease, days,
0.188Median, mean 174,163 154,136a
(range) (100-270) (23-201a)
aOnset of CMV infection was 62 days after transplantation for one patient who probably had a GCV resistant virus. Two patients had no or inadequate CMV
prophylaxis owing to renal failure. Onset of CMV infection for these two patients was 23 days and 32 days after transplantation. For the remaining individuals in
the VGCV group the onset of CMV infection/disease was on average 168 days after transplantation (range: 147 – 201 days).
Johansson et al. BMC Infectious Diseases 2013, 13:582 Page 7 of 10
http://www.biomedcentral.com/1471-2334/13/582
In our study the frequency of ganciclovir resistance
based on treatment failures when using IV ganciclovir
was 2% (2/114). As we did not routinely use CMV DNA
detected by PCR during the study period, GCV resistance
may have been underreported. As only two patients needed
treatment with foscarnet instead of ganciclovir it is also
possible that regular monitoring with quantitative CMV
PCR would not necessarily have meant that more re-
cipients with GCV resistance would have been identified.
The overall incidence of antiviral-resistant CMV in LTRs
has been reported to be 6-9% and in high-risk groups
(D+/R-) 10-27% [23,24].
We found a significant decrease in the rate of acute
rejection in the VGCV group; at 3 and 12 months.
Between 2001 and 2006 there were few if any changes in
the immunosuppression protocol used by our centre and
the significant reduction of acute rejections in the relatively
small VGCV group is therefore an important observation.
One explanation as to why the AR rate decreased
could be that the significantly lower incidence of CMV
infection/disease during the first year post transplant among
those receiving the VGCV prophylaxis represented less
inflammatory response in the transplanted lung(s); which
then triggered fewer episodes of AR. Paraskeva et al
observed a significantly lower incidence of acute rejection
within the first 12 months when VGCV for 5 months was
compared with GCV for 3 months when there was no
difference in the immunosuppression protocols between
the two groups [13]. Jaksch et al found that there was a
non-significant positive trend towards a lower acute
rejection score when D+/R- LTRs received 12 months of
VGCV when compared with 3 months [20]. Cumulative
acute rejection score (CAR) score is not used universally
but many authors have found that it is a useful tool for
measuring and assessing combined severity and frequency
of rejection over time. CAR score and CAR score divided
by the number of evaluable TBBs has been used elsewhere
and reported in other studies [11,13,20,25].
We found a tendency towards lower BOS/OB with
VGVV prophylaxis (24% vs. 32%). Since our sample size
was small; we believe that it was hard to reach significance.
Development of BOS is believed to be an ongoing immuno-
logical process triggered by various factors as frequency
and severity of acute rejections, CMV infection, other
infections, differences in HLA antigens between donor
and recipient as well as other inflammatory processes
[8]. CMV infections usually occur during the first
year post transplantation, it’s therefore not surprising
that when we compared BOS-free 4- year survival
after transplantation in R+, we found no significant
difference between the treatment regimens consider-
ing the limited study population.
Table 4 Incidence of acute rejection (AR) at 3 and 12 months
Oral ganciclovir Valganciclovir p-value
3 months (n = 37) 3 months (n = 51)
CAR scorea, median (quartiles)
3 months 2 (0 – 4) 0 (0 – 2) 0.02
12 months 3 (2 – 6) 1.5 (0 – 3) 0.002
CAR score/TBBb, median (quartiles)
3 months 0.5 (0 - 1) 0 (0 - 0.5) 0.008
12 months 0.43 (0.2-0.67) 0.14 (0-0.5) 0.001
At least one episode of AR grade≥ 1, % (n)
3 months 68% (25/37) 44% (20/45) 0.03
12 months 84% (31/37) 62% (28/45) 0.02
At least one episode of AR grade≥ 2, % (n)
3 months 51% (19/37) 29% (13/45) 0.04
12 months 73% (27/37) 49% (22/45) 0.03
At least two episodes of AR grade≥ 2, % (n)
3 months 24% (9/37) 13% (6/45) n.s
12 months 41% (15/37) 20% (9/45) 0.04
Number of TBB, median (quartiles)
3 months 4 (3 – 4) 4 (3 – 4) n.s
12 months 9 (8 – 9) 8 (6 – 8) 0.001
aCumulative acute rejection score (CAR score) varied between 0 and 6 at 3 months and between 0 and 16 at 12 months.
bCumulative acute rejection score (CAR score) divided by the number of evaluable transbronchial biopsies (TBB).
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The effect on development of BOS associated with CMV
infection/disease as such could be regarded as the negative
impact from CMV infection/disease is stronger than the
difference in impact between the two drugs, it’s therefore
not surprising that greater BOS development is noted for
CMV infection/ disease as such compared to the effect
caused by the difference of the drugs.
BOS-free 4 year survival for R + individuals was 30%
for those with CMV disease and 67% for those without a
CMV infection.
To better evaluate the impact of CMV on BOS
progression we included R- to give a larger study group.
We found that BOS-free 4 year survival for the total group
was 55% and it was lower for those with CMV disease
(32%) compared to the 69% rate for those without CMV
infection (p = 0.005).
Our results support the idea that CMV infection is a
risk factor for onset of BOS. Other studies have pointed
out that CMV infection is one of the reasons for develop-
ment of BOS [9,11-13,17,19,26] yet other studies did not
find that CMV infection had any impact of the onset of
BOS [27,28].
The survival after 6 years (in R + and R-) was 64% for
those diagnosed as having CMV disease (p = 0.042),
55% for those with an asymptomatic CMV infection
(p = 0.018) when compared with patients without CMV
infection (84% survival).
The strength of our study is the long-term follow-up,
verification of CMV diagnosis by using frequent consecu-
tive surveillance TBBs (including IHC for CMV), and the
uniform evaluation and treatment process achieved because
Sahlgrenska is a single centre. FEV1 was followed for
the entire four years. No or minimal changes were
made in the immunosuppressive regimes during the
period 2001-2006. The definition of CMV was identical
throughout the study period.
A limitation is that different CMV prophylaxis drugs were
studied during different periods of time. Another is that
quantitative CMV DNA in serum was not used regularly
during the study period. Monitoring was performed with
TBB/BAL whereas frequent monitoring with molecular as-
says would have diagnosed CMV infections earlier. Con-
founding factors with the potential to reduce the CMV
infection rate may have included more frequent use of tacro-
limus towards the end of the study period - although we do
not believe that this affected our findings. Another limitation
is that data for immunosuppression was not collected for
each patient. In the VGCV group a few more double lung
(DL) transplants were included – this may have brought
about a lowered development of BOS and improved survival.
Conclusions
We observed a lower incidence of CMV infection/disease
and acute cellular rejection during VGCV prophylaxis
when compared with oral GCV – both being administrated
for 3 months. CMV disease/infection was 24% in the
VGCG group and this rate needs to be reduced further. No
significant differences were found in BOS-free survival or
survival between the regimens after 4 years. The impact of
CMV infection/disease in the total group (regardless of
CMV serostatus and prophylaxis) was significant for
BOS-free 4 year survival and 6 year survival.
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